Farglitazar Lacks Antifibrotic Activity in Patients With Chronic Hepatitis C Infection

Gastroenterology

Volumn 138, Issue 4, 2010, Pages

  McHutchison, John ^a   Goodman, Zachary ^b   Patel, Keyur ^a   Makhlouf, Hala ^b   Rodriguez Torres, Maribel ^c   Shiffman, Mitchell ^d   Rockey, Don ^e   Husa, Petr ^f   Chuang, Wan Long ^g   Levine, Robert ^h   Jonas, Mark ⁱ   Theodore, Dickens ^j   Brigandi, Richard ^j   Webster, Alison ^k   Schultz, Margaret ^j   Watson, Helen ^k   Stancil, Britt ^j   Gardner, Stephen ^j  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^c Fundacion de Investigacion de Diego San Juan   (Puerto Rico)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^g KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^h SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

ⁱ Consultants for Clinical Research Inc ^*  (United States)

^j GLAXOSMITHKLINE   (United States)

^k GLAXOSMITHKLINE   (United Kingdom)

more..

Author keywords

Fibrosis; Peroxisome Proliferator Activated Receptor ; Smooth Muscle Actin; Treatment

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN; DIURETIC AGENT; FARGLITAZAR; PEGINTERFERON; PLACEBO; RECOMBINANT INTERFERON; RIBAVIRIN;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; GENE EXPRESSION; HEPATITIS C; HISTOLOGY; HUMAN; JOINT SWELLING; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MORPHOMETRICS; MULTICENTER STUDY; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT GAIN;

EID: 77950201652     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2009.12.003     Document Type: Article

References (30)

1. Liaw Y.F., Sung J.J., Chow W.C., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (2004) 1521-1531
2. Poynard T., McHutchison J., Manns M., et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122 (2002) 1303-1313
3. Friedman S.L. Hepatic fibrosis-overview. Toxicology 254 (2008) 120-129
4. Rockey D.C. Current and future anti-fibrotic therapies for chronic liver disease. Clin Liver Dis 12 (2008) 939-962
5. Miyahara T., Schrum L., Rippe R., et al. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem 275 (2000) 35715-35722
6. Yang L., Chan C.C., Kwon O.S., et al. Regulation of peroxisome proliferator-activated receptor-gamma in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 291 (2006) G902-G911
7. Hazra S., Xiong S., Wang J., et al. Peroxisome proliferator-activated receptor γ induces a phenotypic switch from activated to quiescent hepatic stellate cells. J Biol Chem 279 (2004) 11392-11401
8. Lemberger T., Desvergne B., and Wahli W. Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Annu Rev Cell Dev Biol 12 (1996) 335-363
9. Henke B.R., Blanchard S.G., Brackeen M.F., et al. N-(2-Benzoylphenyl)-L-tyrosine PPARγ agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. J Med Chem 41 (1998) 5020-5036
10. Promrat K., Lutchman G., Uwaifo G.I., et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 39 (2004) 188-196
11. Neuschwander-Tetri B.A., Brunt E.M., Wehmeier K.R., et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone. Hepatology 38 (2003) 1008-1017
12. Rockey D.C., and Chung J.J. Endothelin antagonism in experimental hepatic fibrosis. Implications for endothelin in the pathogenesis of wound healing. J Clin Invest 98 (1996) 1381-1388
13. Rockey D.C., Boyles J.K., Gabbiani G., et al. Rat hepatic lipocytes express smooth muscle actin upon activation in vivo and in culture. J Submicrosc Cytol Pathol 24 (1992) 193-203
14. Ishak K., Baptista A., Bianchi L., et al. Histological grading and staging of chronic hepatitis. J Hepatol 22 (1995) 696-699
15. Poynard T., Ratziu V., McHutchison J., et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 38 (2003) 75-85
16. Kweon Y.O., Goodman Z.D., Dienstag J.L., et al. Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Hepatol 35 (2001) 749-755
17. Belfort R., Harrison S.A., Brown K., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355 (2006) 2297-2307
18. Aithal G.P., Thomas J.A., Kaye P.V., et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 135 (2008) 1176-1184
19. Passariello N., Peluso A., Passariello G., et al. Effects of PPAR-Gamma ligand rosiglitazone on liver fibrosis in chronic hepatitis C patients. J hepatol 46 Suppl 1 (2007) S237
20. Pockros P.J., Jeffers L., Afdhal N., et al. Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-γ1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. Hepatology 45 (2007) 569-578
21. Nelson D.R., Tu Z., Soldevila-Pico C., et al. Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology 38 (2003) 859-868
22. Di Bisceglie A.M., Shiffman M.L., Everson G.T., et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 359 (2008) 2429-2441
23. Abergel A., Darcha C., Chevallier M., et al. Histological response in patients treated by interferon plus ribavirin for hepatitis C virus-related severe fibrosis. Eur J Gastroenterol Hepatol 16 (2004) 1219-1227
24. Feldman P.L., Lambert M.H., and Henke B.R. PPAR modulators and PPAR pan agonists for metabolic diseases: the next generation of drugs targeting peroxisome proliferator-activated receptors?. Curr Top Med Chem 8 (2008) 728-749
25. Manabe N., Chevallier M., Chossegros P., et al. Interferon-α 2b therapy reduces liver fibrosis in chronic non-A, non-B hepatitis: a quantitative histological evaluation. Hepatology 18 (1993) 1344-1349
26. Duchatelle V., Marcellin P., Giostra E., et al. Changes in liver fibrosis at the end of α interferon therapy and 6 to 18 months later in patients with chronic hepatitis C: quantitative assessment by a morphometric method. J Hepatol 29 (1998) 20-28
27. Caballero T., Perez-Milena A., Masseroli M., et al. Liver fibrosis assessment with semiquantitative indexes and image analysis quantification in sustained-responder and non-responder interferon-treated patients with chronic hepatitis C. J Hepatol 34 (2001) 740-747
28. Sakaida I., Nagatomi A., Hironaka K., et al. Quantitative analysis of liver fibrosis and stellate cell changes in patients with chronic hepatitis C after interferon therapy. Am J Gastroenterol 94 (1999) 489-496
29. Kage M., Shimamatu K., Nakashima E., et al. Long-term evolution of fibrosis from chronic hepatitis to cirrhosis in patients with hepatitis C: morphometric analysis of repeated biopsies. Hepatology 25 (1997) 1028-1031
30. Goodman Z.D., Becker Jr. R.L., Pockros P.J., et al. Progression of fibrosis in advanced chronic hepatitis C: evaluation by morphometric image analysis. Hepatology 45 (2007) 886-894